Why Your Oilfield Chemicals Provider Should Sit With Your Engineers

Most operators still treat oilfield chemicals as a counter-sale. A specification goes out, a price comes back, drums arrive, dose rates are set against a months-old recommendation, and the supplier reappears at the next contract cycle. The model is familiar, it is auditable, and it is responsible for a remarkable amount of avoidable production loss across the GCC.

The alternative, where the chemistry partner sits inside the engineering conversation rather than across a procurement counter, is not a marketing flourish. It is a structurally different way of operating that I have watched work, repeatedly, on assets ranging from giant carbonates in the Eastern Province to mature offshore complexes in Abu Dhabi.

What 'across the counter' actually costs

The transactional sourcing model has three predictable failure modes, each of which I have seen drain real money from operators who would never knowingly accept the loss.

• Stale formulation: the chemistry was specified against produced-water samples taken eighteen months ago, the field has watered up and shifted ionic balance, and the molecule is now operating outside its design envelope.
• Stale dose rate: continuous-injection rates are anchored to a commissioning recommendation that nobody has revisited, even as the failure mode has migrated from scale to mixed scale-and-corrosion.
• Stale deployment: the squeeze design, the injection-point selection, or the carrier-fluid choice was made for an earlier well architecture and nobody on the supplier side has the standing to suggest revisiting it.

Each of those failures is invisible on the procurement dashboard. The chemical is being delivered, the invoices are being paid, the dose rates are being met. The only visible signal is a slow drift in well performance that gets attributed to reservoir behaviour, and the conversation never reaches the chemistry.

What changes when chemistry is in the room

When the chemistry partner is treated as a member of the engineering team, the conversation rearranges itself. The first thing that changes is data flow: the partner sees the produced-water analyses, the corrosion-coupon results, the workover histories, the artificial-lift performance data. None of that is normally shared with a transactional supplier, and the absence of it is precisely why their recommendations stay generic.

The second change is meeting cadence. A chemistry partner embedded in the asset team is in the production-optimisation review every month, the integrity meeting every quarter, the well-intervention planning sessions before the workovers are scheduled. The chemistry is then designed against decisions that are about to be made, not decisions that were made eighteen months ago.

"Chemistry that is not in the room when the field decisions are taken is, by definition, reacting to those decisions rather than informing them."

A worked example: integrated water-injection chemistry

An asset team I worked with for several years was running a large water-injection scheme with three separate chemical contracts: one for biocide, one for scale inhibition on the injection side, one for corrosion control. Each contract had been competitively tendered, each supplier was reputable, and the integrated system was a quiet disaster. The biocide was incompatible with the corrosion inhibitor at the dose ratios being used at the manifold. The scale inhibitor was hydrolysing under the bacterial regime that the biocide was failing to fully suppress. The corrosion package was being consumed by the breakdown products of the other two.

None of the three suppliers was wrong about their own product. None of them had been asked, or empowered, to think about the system. When we restructured the engagement so that a single chemistry partner sat inside the integrity team and owned the system performance rather than the individual products, the combined chemical opex dropped by roughly twenty-five per cent and the injectivity index recovered noticeably within a year.

The engineering questions a counter-supplier cannot answer

There is a fairly specific set of questions that an engineering-embedded chemistry partner can answer and a transactional supplier structurally cannot. They are worth listing because they map almost exactly onto the value that gets lost in the transactional model.

• Should this well be on continuous injection, periodic squeeze, or a hybrid, given its current decline profile and intervention economics?
• Is the corrosion failure at the bottom of the riser a film-redistribution issue or an actual chemistry compatibility issue with the demulsifier upstream?
• Can we change the carrier solvent on the paraffin inhibitor to remove the cold-morning gelling problem the operations team has been working around for two years?
• Is the dose rate creep we are seeing a brine-chemistry change, a flow-regime change, or a quality-control issue at the manufacturing batch level?
• If we accelerate the workover schedule on this pad, what changes about the chemistry programme, and can we run a leaner package between now and then?

Why operators resist the model

The honest objection is that embedding a chemistry partner inside the engineering team feels like a loss of procurement leverage. If the same partner is designing the chemistry, recommending the dose rate, and supplying the product, where is the competitive tension?

It is a fair concern and there is a clean answer to it. The engagement structure that works separates the design fee from the supply margin, exposes the formulation and the manufacturing batch records to the operator, and writes performance-based exit clauses into the contract. The operator retains the leverage; what changes is that the leverage is now applied to outcomes rather than to per-litre price. In every engagement of that shape I have been part of, the operator has come out materially ahead on total cost and meaningfully ahead on production reliability.

What the integrated model looks like in practice

1. 01A discovery phase in which the chemistry partner reviews the full asset data, not just the chemical-spec sheet: produced fluids, integrity history, workover records, artificial-lift performance.
2. 02A formulation review against the actual current operating envelope, with field-representative testing where the existing programme has drifted out of validity.
3. 03An embedded review cadence: monthly with operations, quarterly with integrity, before every major intervention.
4. 04Transparent pricing with the design and the supply unbundled, so the operator can see what is being paid for which work.
5. 05Performance metrics tied to production and integrity outcomes rather than to delivered drum volumes.

The track record this rests on

I am occasionally asked why I am confident this model works, given that most of the GCC industry still operates on the counter-sale default. The answer is that the technologies I commercialised inside Aramco, including the production-chemistry platforms recognised with two World Oil Awards and the Innovation Board Award, only worked because the chemistry was inside the engineering conversation. The patents, the papers, the half-billion-plus in attributable production value, none of that was generated by drums on a procurement contract. It was generated by chemists sitting next to engineers and operators, week after week, on real assets.

"The chemistry that earned the awards was the chemistry that had been in the room when the field decisions were taken. That is not a coincidence; that is the mechanism."

What to do about it on Monday

If you are running a producing asset and your chemical programme is structured as a series of discrete supply contracts, there is a useful diagnostic exercise that takes about a week. Pull the produced-water analyses for your top ten wells, the corrosion coupon data for the past three years, and the chemical purchase records over the same period. Lay them next to the production curves. The story those four datasets tell, when read together, is almost always different from the story any one of them tells alone.

When that diagnostic surfaces a gap, our work at /services/chemistry is to close it: bespoke formulation where catalogue chemistry has drifted, integrated supply where fragmented contracts are interfering with each other, and embedded engineering support where the asset team needs chemistry in the room rather than across the counter. The conversation usually starts with whatever data you already have.